Acknowledgements
I am grateful to Dr Masaru Ubasawa for helpful discussions and careful reading of this manuscript. Footnotes
* Tel: +81-45-963-3401; Fax: +81-45-963-3890; E-mail: [email protected] References Top
Pyrophosphorolysis and...
Mutation studies
Protein priming
Novel drug candidates
References
1. Locarnini, S. A. & Newbold, J. E. (1997). Chronic hepatitis B: the therapeutic challenge. Journal of Antimicrobial Chemotherapy 39, 559–65.[Free Full Text] 2. Seeger, C. & Mason, W. S. (2000). Hepatitis B virus biology. Microbiology and Molecular Biology Reviews 64, 51–68.[Abstract/Free Full Text] 3. Lok, A. S. & McMahon, B. J. (2001). Chronic hepatitis B. Hepatology 34, 1225–41.[CrossRef][Medline] 4. Chang, C.-N., Doong, S.-L., Zhou, J. H., Beach, J. W., Jeong, L. S., Chu, C. K. et al. (1992). Deoxycytidine deaminase-resistant stereoisomer is the active form of (±)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication. Journal of Biological Chemistry 267, 13938–42.[Abstract/Free Full Text] 5. Arion, D., Kaushik, N., McCormick, S., Borkow, G. & Parniak, M. A. (1998). Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37, 15908–17.[CrossRef][Medline] 6. Meyer, P. R., Matsuura, S. E., So, A. G. & Scott, W. A. (1998). Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proceedings of the National Academy of Sciences, USA 95, 13471–6.[Abstract/Free Full Text] 7. Arion, D., Sluis-Cremer, N. & Parniak, M. A. (2000). Mechanism by which phosphonoformic acid resistance mutations restore 3'-azido-3'-deoxythymidine (AZT) sensitivity to AZT-resistant HIV-1 reverse transcriptase. Journal of Biological Chemistry 275, 9251–5.[Abstract/Free Full Text] 8. Crowther, R. A., Kiselev, N. A., Bottcher, B., Berriman, J. A., Borisova, G. P., Ose, V. et al. (1994). Three-dimensional structure of hepatitis B virus core particles determined by electron cryomicroscopy. Cell 77, 943–50.[Medline] 9. Urban, S., Urban, S., Fischer, K. P. & Tyrrel, D. L. (2001). Efficient pyrophosphorolysis by a hepatitis B virus polymerase may be a primer-unblocking mechanism. Proceedings of the National Academy of Sciences, USA 98, 4984–9.[Abstract/Free Full Text] 10. Stuyver, L. J., Locarnini, S. A., Lok, A., Richman, D. D., Carman, W. F., Dienstag, J. L. et al. (2001). Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33, 751–7.[CrossRef][Medline] 11. Wilson, J. E., Aulabagh, A., Caligan, B., McPherson, S., Wakefield, J. K., Jablonski, S. et al. (1996). Human immunodeficiency virus type-1 reverse transcriptase, contribution of Met-184 to binding of nucleoside 5'-triphosphate. Journal of Biological Chemistry 271, 13656–62.[Abstract/Free Full Text] 12. Sarafianos, S. G., Kalyan, D., Clark, A. D., Jr, Ding, J., Boyer, P. L., Hughes, S. H. et al. (1999). Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with ß-branched amino acids. Proceedings of the National Academy of Sciences, USA 96, 10027–32.[Abstract/Free Full Text] 13. Gao, H.-Q., Boyer, P. L., Sarafianos, S. G., Arnold, E. & Hughes, S. H. (2000). The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase. Journal of Molecular Biology 300, 403–18.[CrossRef][Medline] 14. Das, K., Xiong, X., Yang, H., Westland, C. E., Gibbs, C. S., Sarafianos, S. G. et al. (2001). Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). Journal of Virology 75, 4771–9.[Abstract/Free Full Text] 15. Gaillard, R. K., Barnard, J., Lopez, V., Hodges, P., Bourne, E., Johnson, L. et al. (2002). Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity. Antimicrobial Agents and Chemotherapy 46, 1005–13.[Abstract/Free Full Text] 16. Ono-Nita, S. K., Kato, N., Shiratori, Y., Kato, J., Goto, T., Schinazi, R. F. et al. (2001). The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. Journal of Clinical Investigation 107, 449–55.[Abstract/Free Full Text] 17. Ono-Nita, S. K., Kato, N., Shiratori, Y., Carrilho, F. J. & Omata, M. (2002). Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus. Antimicrobial Agents and Chemotherapy 46, 2602–5.[Abstract/Free Full Text] 18. Perrillo, R., Schiff, E., Yoshida, E., Statler, A., Hirsch, K., Wright, T. et al. (2000). Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 32, 129–34.[Medline] 19. Wang, G. H. & Seeger, C. (1992). The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis. Cell 71, 663–70.[Medline] 20. Innaimo, S. F., Seifer, M., Bisacchi, G. S., Standring, D. N., Zahler, R. & Colonno, R. J. (1997). Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrobial Agents and Chemotherapy 41, 1444–8.[Abstract] 21. Seifer, M., Hamatake, R. K., Colonno, R. J. & Standring, D. N. (1998). In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrobial Agents and Chemotherapy 42, 3200–8.[Abstract/Free Full Text] 22. Donnaoui, E., Trépo, C. & Zolium, F. (1997). Inhibitory effect of penciclovir-triphosphate on duck hepatitis B virus reverse transcription. Antiviral Chemistry and Chemotherapy 8, 38–46. 23. Wang, X. & Hu, J. (2002). Distinct requirement for two stages of protein-primed induction of reverse transcription in hepadnaviruses. Journal of Virology 76, 5857–65.[Abstract/Free Full Text] 24. Delaney, W. E., IV, Edwards, R., Colledge, D., Show, T., Furman, P., Painter, G. et al. (2002). Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrobial Agents and Chemotherapy 46, 3057–60.[Abstract/Free Full Text] 25. Kamiya, N., Kubota, A., Iwase, Y., Sekiya, K., Ubasawa, M. & Yuasa, S. (2002). Antiviral activities of MCC-478, a novel and specific inhibitor of hepatitis B virus. Antimicrobial Agents and Chemotherapy 46, 2872–7.[Abstract/Free Full Text] 26. Yuasa, S., Kamiya, N. & Marion, P.L. (2001). Evaluation of anti-hepadnaviral activity of a novel PMEA derivative in DHBV-infected duck models. In Program and Abstracts of the Fifty-second Annual Meeting of the American Association for the Study of Liver Disease, Dallas, TX, 2001. Abstract 587, p. 319A. American Association for the Study of Liver Disease, Alexandria, VA, USA. 27. Yuasa, S., Kamiya, N., Yamabe, K., Yamaguchi, Y. & Tennant, B. C. (2001). Potent and sustained antiviral effect of MCC-478 (LY582563) in the woodchuck model of hepatitis B virus infection. In Program and Abstracts of the Fifty-second Annual Meeting of the American Association for the Study of Liver Disease, Dallas, TX, 2001. Abstract 592, p. 320A. American Association for the Study of Liver Disease, Alexandria, VA, USA. |